ProofPilot, a prominent end-to-end clinical experience platform known for its innovative solutions, has officially announced its acquisition of Lokavant. This leading clinical trial intelligence company excels in providing predictive analytics specifically designed for clinical research. This strategic acquisition merges ProofPilot’s robust trial execution capabilities with Lokavant’s cutting-edge analytics technology, creating an unparalleled platform that empowers sponsors and research organizations to enhance clinical research efficiency and expedite the delivery of new therapies to patients.
Lokavant, which spun out of Roivant in 2020, has developed advanced technology that harnesses both historical and real-time data to deliver valuable predictive insights. These insights are crucial for optimizing study feasibility, enabling researchers to assess the likelihood of success for clinical trials and mitigate operational risks that may arise during study conduct. By integrating Lokavant’s sophisticated analytics into the ProofPilot platform, sponsors and contract research organizations (CROs) are now equipped to holistically design and execute intricate clinical trial experiences while proactively anticipating potential challenges. This capability enables quicker and more reliable outcomes, which are essential for the timely development of new therapies.
The newly combined platform presents a comprehensive, data-driven approach to trial management, featuring an intuitive and user-friendly interface for clinical researchers. With AI-powered study forecasting, users can engage in proactive scenario planning, enabling them to prepare for various potential outcomes. Additionally, the platform provides tools for creating and managing targeted recruitment campaigns, accompanied by real-time performance dashboards that offer ongoing monitoring throughout the entire study execution process.
Moreover, the integrated platform includes enhanced study oversight capabilities, which significantly improve the quality of collected data and ensure compliance. These capabilities are driven by site training that responds to emerging signals regarding site protocol adherence and overall data quality. This comprehensive integration not only enhances operational predictability and reduces risk, but it also ensures that clinical trials deliver reliable and actionable results. Ultimately, this leads to a more streamlined process for bringing innovative therapies to patients who need them.
With the successful acquisition of Lokavant, the company now offers a fully integrated end-to-end platform that seamlessly combines digital trial planning, execution, and predictive intelligence, all aimed at maximizing operational performance and fostering the development of new medical advancements. And this integration represents a significant leap forward in the capabilities available to researchers and sponsors in the clinical trial landscape.
KEY QUOTES:
“ProofPilot has long demonstrated a commitment to empowering sponsors and research teams with the tools they need to execute successful trials. By bringing Lokavant’s predictive analytics engine into our platform, we’re equipping our customers with an industry first ability to measure and predict success in real time by combining study stakeholder behaviors and real time study data.”
Chris Venezia, CEO of ProofPilot
“We are excited to see Lokavant join forces with ProofPilot. This move aligns deeply with Roivant’s mission—to improve the lives of patients by accelerating the development and commercialization of medicines that matter. By combining Lokavant’s powerful, data-driven insights with ProofPilot’s trial experience platform, biopharma will be better positioned to deliver innovative medicines and technologies faster, more precisely, and with greater impact for patients everywhere.”
Alex Gasner, EVP Roivant Health
“This is a transformative moment for both ProofPilot and Lokavant. By combining ProofPilot’s innovative trial platform with Lokavant’s predictive analytics, we are giving sponsors and CROs unprecedented clarity and foresight into study performance. Together, we empower them to plan smarter, adapt faster, and bring new therapies to patients more efficiently—setting a new standard for how clinical trials are designed and executed.”
Rohit Nambisan, CEO & Co-Founder of Lokavant
